Navigation Links
Oral bacteria may signal pancreatic cancer risk
Date:9/18/2012

biologist, said the importance of bacteria in cancer is growing. "The impact of immune defense against both commensals and pathogenic bacteria undeniably plays a role," he said. "We need to further investigate the importance of bacteria in pancreatic cancer beyond the associated risk."

Prospective, controlled study

To conduct their research, Michaud and Izard drew on medical records and preserved blood samples collected by the Imperial College-led European Prospective Investigation into Cancer and Nutrition Study, a massive dataset of more than 500,000 adults in 10 countries. Detailed health histories and blood samples are available from more than 380,000 of the participants.

From that population, the researchers found 405 people who developed pancreatic cancer, but no other cancer, and who had blood samples available. The researchers also selected 416 demographically similar people who did not develop pancreatic cancer for comparison.

The researchers blinded themselves to which samples came from cancer patients and which didn't during their analysis of the blood, which consisted of measuring antibody concentrations for 25 pathogenic and commensal oral bacteria. In their study design and analysis they controlled for smoking, diabetes, body mass index, and other risk factors.

An important element of the study design was that date of the blood samples preceded the diagnosis of pancreatic cancer by as much as a decade, meaning that the significant difference in antibody levels were likely not a result of cancer.

Instead, the underlying mechanisms that link Porphyromonas gingivalis to pancreatic cancer could be causal, Michaud said, although much more research is needed to understand this association.

Meanwhile, the researchers speculate, the association of high levels of antibodies for commensal bacteria and pancreatic cancer, may indicate an innate, highly active immune response that is prote
'/>"/>

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Discovery of essential genes for drug-resistant bacteria reveals new, high-value drug targets
2. Superpowered Bacteria May Lurk Behind Sinus Infections
3. Feces-Linked Bacteria Found at Lake Erie Beaches
4. Could Bacteria in Skin Mites Help Cause Rosacea?
5. New antibacterial coating for sutures could reduce infections after surgery
6. Trudeau researchers identify unforeseen regulation of the anti-bacterial immune response
7. Microbiology and Genome Experts Quell Deadly Bacteria Outbreak
8. NIH uses genome sequencing to help quell bacterial outbreak in Clinical Center
9. Genes carried by E. coli bacteria linked to colon cancer
10. Protective bacteria in the infant gut have resourceful way of helping babies break down breast milk
11. Chronic exposure to staph bacteria may be risk factor for lupus, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Oral bacteria may signal pancreatic cancer risk
(Date:3/2/2015)... 02, 2015 Formetco today announced the ... The FTX uses state-of-the-art technology to deliver an ... and owner satisfaction. An item of particular value, ... Formetco 10 year LED Brightness Warranty. , Why the ... a superior billboard among any other billboard product in ...
(Date:3/2/2015)... 02, 2015 Calvary Hospital recently ... Brooklyn Satellite in Lutheran Medical Center, with the ... must demonstrate excellence through clinical expertise as well ... to go above and beyond to make a ... patients and their families. Award recipients are chosen ...
(Date:3/2/2015)... Getting customers to discover a whole ... this March as the 31st annual Frozen Food Month ... Frozen & Refrigerated Foods Association (NFRA) to stimulate the ... than 20 delicious frozen selections and is thrilled to ... frozen options are crafted with simple ingredients, no preservatives ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Today ... Luis Obispo), in partnership with the California Healthcare ... Disorders (NORD), presented an Assembly resolution recognizing Feb. ... families and healthcare professionals caring for millions of ... is a nonprofit, public policy research organization, representing ...
(Date:3/2/2015)... York, New York (PRWEB) March 02, 2015 ... behalf of women who were allegedly harmed by the ... state and federal courts around the U.S., according to ... U.S. District Court, Eastern District of California on February ... a case pending in that jurisdiction may pursue her ...
Breaking Medicine News(10 mins):Health News:Formetco Launches Innovative LED Billboard System 2Health News:Calvary Hospital Honors Peter Acerios, RN, with Daisy Award 2Health News:Take a Fresh Look at Frozen with Ian’s 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 4
... Cost Saving Benefit Faces Eventual Elimination Without Relief ... support of President Obama,s pledge not to raise taxes on ... -- outside of the normal legislative process -- adopting provisions ... restrict the use of flexible spending accounts (FSAs) in order ...
... Oct. 14 New Enterprise Associates, Inc. (NEA), a leading ... has been promoted to General Partner. Dr. Viswanathan, who joined ... equity information technology investments, as well as the firm,s activities ... Principal. Dr. Torti joined NEA in 2007 and is focused ...
... Networks , the nation,s leading provider of physician office-based ... consumer purchase behavior, not just purchase intent, for OTC ... revenue and justify investments designed to capture market share, ... health messages to purchase volume. To address this need ...
... aged 70-79, the apparent association between light-to-moderate alcohol consumption ... not hold up after adjustments were made for characteristics ... education, and income. The authors of the ... American Geriatrics Society , say this suggests that life-style ...
... SAN DIEGO, Oct. 14 Cardium Therapeutics (NYSE Amex: ... Matrix Phase 2b clinical trial of Excellarate(TM) for the ... ulcers based on the Company,s Gene Activated Matrix (GAM) ... the Excellarate product candidate (GAM501, which is a combination ...
... Continuing its efforts to educate, inform, and empower ... patient-focused organization, is hosting its 25-minute live call-in show, ... Monday, October 19, 2009 at 6:00 PM on Channel ... frank discussion regarding Retail Health Clinics with Erin Buckley, ...
Cached Medicine News:Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 2Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 3Health News:'Beneficial' effects of alcohol? 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 3Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 4Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 5Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 6Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 7Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 8Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 9Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 10Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 11Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 12Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 13Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 14Health News:Retail Health Clinics - The Real Story 2
(Date:3/2/2015)... March 2, 2015 Cure SMA recently announced a ... Biomedical Research (CALIBR). This funding is an extension of a ... a $700,000 Cure SMA grant to Dr. Peter G. ... "Optimization of Small Molecules that Increase SMN2 Levels ... motor neuron (SMN) protein is critical to the function of ...
(Date:3/2/2015)...  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... for the fiscal first quarter 2015 after the market ... The Company will also host a conference call for ... Central Time (10:00 a.m. Eastern Time). Investors may access ...
(Date:3/2/2015)... 2015 Amgen (NASDAQ: AMGN ) ... data evaluating Repatha TM (evolocumab), an investigational cholesterol-lowering ... for chronic heart failure, at the upcoming American College ... being held March 14-16 in San Diego ... monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 ...
Breaking Medicine Technology:Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3Landauer, Inc. Announces Date and Time for Announcement of Fiscal First Quarter 2015 Results and Conference Call 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 4Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 5Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 6Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 7Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 8Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 9Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 10Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 11
... in Poor Risk Frontline Elderly AML and in Combination with Cytarabine ... Call Scheduled for Tuesday, December 9 at 11:00 am ET to ... , SAN FRANCISCO , Dec. 7 ... the presentation of new data from two ongoing clinical trials demonstrating ...
... carisbamate, an,investigational compound recently filed with the FDA for ... 16 years of age and,older, was presented today during ... American Epilepsy Society. , ... efficacy, safety and tolerability of carisbamate as an,adjunctive treatment ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 2Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 3Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 4Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 5
... 4420 Colloid Osmometer. Rapid measurement of ... prediction of edema onset in clinical ... sample and reference chambers to simulate ... membrane in the establishment of osmotic ...
... Automated Cortisol assay with flexible ... workflow, Excellent correlation and agreement ... confidence,in assay performance, Standardized to ... Panels delivers assurance in,accuracy of ...
Quantitative determination of cortisol levels in serum and urine. Cross-reactivity with dexamethasone: 0.2% (suppression test).Time to first result: 30 minutes....
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
Medicine Products: